ReviewProstate cancer and prostatic diseases2011
Emerging therapeutic approaches in the management of metastatic castration-resistant prostate cancer.
Review in Prostate cancer and prostatic diseases, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed.
- The effect of clinical trial participation versus non-participation on overall survival in men receiving first-line docetaxel-containing chemotherapy for metastatic castration-resistant prostate cancer.BJU international · 2012Trial
- Review
- Peptide Modification Diminishes HLA Class II-restricted CD4International journal of molecular sciences · 2022Article
- Endocrine consequences of treatment with the new androgen receptor axis-targeted agents for advanced prostate cancer.Hormones (Athens, Greece) · 2021Review
- Angiogenesis Inhibition in Prostate Cancer: An Update.Cancers · 2020Review
- Impact of clinical trial participation on survival in patients with castration-resistant prostate cancer: a multi-center analysis.BMC cancer · 2018Article
- Combining immune check-point blockade and cryoablation in an immunocompetent hormone sensitive murine model of prostate cancer.Prostate cancer and prostatic diseases · 2018Article
- Prostate Cancer Immunotherapy: Exploiting the HLA Class II Pathway in Vaccine Design.Journal of clinical & cellular immunology · 2015Article
- The potential of neurotensin secreted from neuroendocrine tumor cells to promote gelsolin-mediated invasiveness of prostate adenocarcinoma cells.Laboratory investigation; a journal of technical methods and pathology · 2015Article
- Association of pretreatment neutrophil-to-lymphocyte ratio (NLR) and overall survival (OS) in patients with metastatic castration-resistant prostate cancer (mCRPC) treated with first-line docetaxel.BJU international · 2014Article
- Novel therapies for the treatment of advanced prostate cancer.Current treatment options in oncology · 2013Review
- The changing landscape of treatment options for metastatic castrate-resistant prostate cancer: challenges and solutions for physicians and patients.P & T : a peer-reviewed journal for formulary management · 2012Article
- Biomarkers in the management and treatment of men with metastatic castration-resistant prostate cancer.European urology · 2012Review
- The unfolding treatment landscape for men with castration-resistant prostate cancer.Clinical investigation · 2011Article
- Abiraterone acetate for prostate cancer: a new era of hormonal therapies.Asian journal of andrology · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Although treatment options for men with castration-resistant prostate cancer (CRPC) have improved with the recent and anticipated approvals of novel immunotherapeutic, hormonal, chemotherapeutic and bone-targeted agents, clinical benefit with these systemic therapies is transient and survival times remain unacceptably short. Thus, we devote the second section of this two-part review to discussing emerging therapeutic paradigms and research strategies that are entering phase II and III clinical testing for men with metastatic CRPC. We will discuss a range of emerging hormonal, immunomodulatory, antiangiogenic, epigenetic and cell survival pathway inhibitors in current clinical trials, with an emphasis on how these therapies may complement our existing treatment options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.